Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who ... Read More

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

“I am very encouraged to see that INZ-701 may improve vascular pathology and believe that this effect may translate to clinical benefits in patients of all ages.” The ongoing ... Read More

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

The poster presentation #CT068: “Interim results of the ongoing phase 1/2 ... release syndrome in any patient at any dose level “We are pleased to present our progress on the VISTA-101 clinical trial ... Read More

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

April 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc ... help patients fight cancer, today announced updated interim survival data from the ongoing randomized phase 2 clinical trial ... Read More

Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

Top-line data ... trial of KP1077 in patients with IH. The Company plans to request an end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration to seek guidance on the Phase 3 ... Read More

NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference

March 25, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc ... Phase 1 clinical trial data on the use of its investigational autologous NK cell therapy, SNK01, to treat patients with Alzheimer’s ... Read More

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

Viking also plans to initiate a Phase 2 trial of oral VK2735 in patients with obesity in the second half of 2024. The Phase 1 MAD study of oral VK2735 is an extension of the company's Phase 1 ... Read More

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Forward-Looking Statements This press release contains ... the registrational Phase 3 RECOVER-2 trial, the Company’s expectations regarding the anticipated clinical profile of its product ... Read More

ATXS Astria Therapeutics, Inc.

Astria Therapeutics, Inc., a biopharmaceutical company ... a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. Read More

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

The poster presentation #CT068: “Interim results of the ongoing phase 1/2 ... release syndrome in any patient at any dose level “We are pleased to present our progress on the VISTA-101 ... Read More

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Forward-Looking Statements This press release contains ... the registrational Phase 3 RECOVER-2 trial, the Company’s expectations regarding the anticipated clinical profile of its product ... Read More

Kineta, Inc.: Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

The company's immuno-oncology pipeline includes KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients ... This press release contains "forward-looking ... Read More